Abstract
Experimental evidence suggests that the protein phosphatase calcineurin mediates the action of amyloid-β (Aβ) oligomers, the most toxic amyloid species thought to drive initial cognitive decline in Alzheimer's disease (AD). However, there is currently no evidence that inhibition of calcineurin could prevent the onset of AD in humans. Here, we report for the first time that individuals chronically treated with calcineurin inhibitors to prevent solid organ transplant rejection have a significantly lower incidence of AD/dementia as compared to the general population. This result prompts further clinical development of calcineurin inhibition as a viable treatment for AD.
Original language | English (US) |
---|---|
Pages (from-to) | 329-333 |
Number of pages | 5 |
Journal | Journal of Alzheimer's Disease |
Volume | 47 |
Issue number | 2 |
DOIs | |
State | Published - Jul 24 2015 |
Keywords
- Alzheimer's disease
- FK506
- calcineurin
- dementia
- solid organ transplant
ASJC Scopus subject areas
- General Neuroscience
- Clinical Psychology
- Geriatrics and Gerontology
- Psychiatry and Mental health